Addressing an unmet medical need in GERD
Highlights from the 2024 Annual Report: Market overview. Significant proportion of severe eGERD patients treated by Gastroenterologists remain unhealed with PPI treatment.
Read more
In the spotlight
Check out the latest updates from Cinclus Pharma
A Doctor’s perspective on linaprazan glurate’s unique potential
Highlights from the 2024 Annual Report: Interview with Dr. Prateek Sharma. Dr. Prateek Sharma, Medical Advisor and expert in gastrointestinal diseases and cancer, shares his insights on its safety and potential usage areas.
Read more
Nina Rawal, Trill Impact Ventures, on the investment in Cinclus Pharma
Highlights from the 2024 Annual Report: Interview with Nina Rawal. Trill Impact Ventures views Cinclus Pharma as a strong Life Science candidate with the potential to address unmet medical needs in GERD and H. pylori. Nina Rawal, Co-Head of Ventures and a board member at Cinclus Pharma, contributes her biomedical expertise and financing experience.
Read more